Navigation Links
Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
Date:2/25/2011

nally, numerous health organizations and institutions have stated that Auralgan is safe and effective.  The United States National Library of Medicine's Medline Plus and the National Institute of Health's National Center for Biotechnology Information have stated on their webpages that Auralgan is a safe and effective treatment for ear pain and inflammation associated with AOM.  The American Academy of Pediatric and American Academy of Family Physicians along with the Institute for Clinical Systems Improvement published guidances recognizing Auralgan as a safe and effective treatment for ear pain in pediatric patients with AOM.

According to Mr. Preston, when Deston acquired Auralgan, it believed that this product qualified as an "old drug" because of the long marketing of Auralgan, the evidence supporting its safe and effective use, and the fact that the Federal Government has never concluded that it was a "new drug" or took action against the previous manufacturer of Auralgan.  

Deston was unaware that FDA believed that Auralgan was a "new drug" until the FDA informed Deston of this position last year.  In response to this information, Deston's legal counsel prepared and filed, on May 28, 2010, a "Citizen Petition" with the FDA, to make the case, point by point, why Auralgan was not a 'new drug'. Deston had expected a due process period whereby FDA would provide an in-kind formal response, explaining why they believed it was a 'new drug'.

Deston also began discussions with FDA regarding how to obtain FDA approval for Auralgan if, after addressing the Citizen Petition, the FDA decided the product qualified as a "new drug."  On February 15, 2011 – a day after the Federal Government seized Auralgan – Deston received a partial response to its Citizen Petition implying that the FDA has not yet made a determination on whether Auralgan qualifies as a "new drug" or an "old drug."  Because FDA has yet to review
'/>"/>

SOURCE Deston Therapeutics LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
(Date:9/16/2014)... activity monitors hold great promise in helping people ... increasingly sophisticated devices help the wearers improve their ... responses. This information is organized into companion computer ... large and quickly growing market for these devices, ... at Galveston analyzed 13 of these activity monitors, ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... DC (PRWEB) September 16, 2014 Programs ... potentially yield hundreds of billions of dollars in savings ... report by the Commonwealth Fund. To help spur these ... seeking up to 10 collaborative groups from across the ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed to ...
(Date:9/16/2014)... 16, 2014 Who:, The Pulmonary Hypertension ... Campus and Children’s Hospital Colorado are hosting ... country’s leading pulmonary hypertension association that works to find ways ... of the lungs that affects the functioning of the heart ... survivability is only 2.8 years. , What:, Colorado PH ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... Push for More Charity Care After County,Assessor Reports ... CHICAGO, Nov. 8 Joined by union ... on Thursday,said the State and County should require ... justify their tax exemptions by providing more,charity care ...
... Adaptis, a business integration,provider focused exclusively on ... Inc., has purchased HealthASPex (HAX) through an,asset ... and PPO routing,services to Third Party Administrators ... http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) "Tela,s streamlined front-end ...
... and e-Health, a publication available in print and on-line by ... expand its content and frequency beginning in 2008; a new ... issue. , A new format ... enables more news, roundtable discussions, case studies, interviews with leaders ...
... topic of cancer prevention is covered widely in the ... information and complex scientific research that is not easily ... for Cancer Research (AACR) and Susan G. Komen for ... scientific research community and journalists who cover cancer science ...
... Make Breast Cancer ... Nov. 8 Washington State has the highest rate,of breast ... of Susan G. Komen for the Cure will host a ... policymakers to increase the budget for,screening programs for low-income women ...
... Develop a New Thrombectomy ... to Remove Clots in Blood Vessels, ST. PAUL, Minn., ... Dakota state lawmakers, with the support of Governor John Hoeven,and ... for Enova Medical Technologies, the University of North Dakota (UND),and ...
Cached Medicine News:Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 2Health News:Charity Care Hospitals Told to Put Up or Pay Up in Wake of New Report 3Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2Health News:Telemedicine publication expands coverage 2Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:North Dakota Grants Enova Medical Technologies a $2.5 Million Centers of Excellence Grant 2
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
Medicine Products: